Absorbable polymer stent technologies for vascular regeneration

Journal of Chemical Technology and Biotechnology

Volumn 85, Issue 6, 2010, Pages 744-751

  Grabow, Niels ^a   Martin, David P ^b   Schmitz, Klaus Peter ^a   Sternberg, Katrin ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b TEPHA INC   (United States)

Author keywords

Degradation; Drug elution; Polymer; Stent

Indexed keywords

4-HYDROXYBUTYRATE; ABSORBABLE POLYMERS; CLINICAL USE; CORONARY ARTERY DISEASE; DEGRADABLE POLYMERS; DRUG ELUTION; DRUG-ELUTING STENTS; ENGINEERING PERSPECTIVE; IN-STENT RESTENOSIS; LOCAL DRUG DELIVERY; LONG-TERM SAFETY; MECHANICAL FUNCTIONS; METAL STENTS; PERIPHERAL ARTERIAL OCCLUSIVE DISEASE; POLY LACTIC ACID; POLYMER COATING; POLYMERIC MATERIAL; SECOND GENERATION; VASCULAR INTERVENTIONS;

DEGRADATION; DISEASES; DRUG DELIVERY; POLYMER BLENDS; POLYMERS;

PLASTIC COATINGS;

HYDROXYBUTYRIC ACID; POLY(4 HYDROXYBUTYRATE); POLYLACTIC ACID; UNCLASSIFIED DRUG;

ANGIOGENESIS; BARE METAL STENT; BIODEGRADABILITY; BIOENGINEERING; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; HEALING IMPAIRMENT; IN-STENT RESTENOSIS; MATERIAL COATING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; SHORT SURVEY; THROMBOSIS;

EID: 77952570637     PISSN: 02682575     EISSN: 10974660     Source Type: Journal    
DOI: 10.1002/jctb.2282     Document Type: Short Survey

References (80)

1. Dotter CT, Transluminally-placed coilspring endarterial tube grafts. Long-term patency in canine popliteal artery. Invest Radiol 4:329-332 (1969).
2. Hanawa T,Materials formetallic stents. J Artif Organs 12:73-79 (2009).
3. Gruntzig AR, Senning A and Siegenthaler WE, Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 301:61-68 (1979).
4. Sigwart U, Puel J, Mirkovitch V, Joffre F and Kappenberger L, Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316:701-706 (1987).
5. Palmaz JC, Kopp DT, Hayashi H, Schatz RA, Hunter G, Tio FO, et al, Normal and stenotic renal arteries: experimental balloonexpandable intraluminal stenting. Radiology 164:705-708 (1987).
6. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, RutschW, Heyndrickx G, et al, A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331:489-495 (1994).
7. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al, A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331:496-501 (1994).
8. Holmes DR, Jr., Hirshfeld J, Jr., Faxon D, Vlietstra RE, Jacobs A and King SB, 3rd, ACC expert consensus document on coronary artery stents. Document of the American College of Cardiology. J Am Coll Cardiol 32:1471-1482 (1998).
9. Kraitzer A, Kloog Y and Zilberman M, Approaches for prevention of restenosis. J Biomed Mater Res B Appl Biomater 85:583-603 (2008).
10. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al, A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780 (2002).
11. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al, Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323 (2003).
12. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al, A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350:221-231 (2004).
13. Tanne JH, Use of drug eluting stents increases in the US but only for some groups. Br Med J 329:1205 (2004).
14. Nebeker JR,Virmani R, Bennett CL,Hoffman JM, SamoreMH,Alvarez J, et al, Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47:175-181 (2006).
15. Thom T, Haase N, RosamondW, Howard VJ, Rumsfeld J, Manolio T, et al, Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113:85-151 (2006).
16. Serruys PW, Kutryk MJ and Ong AT, Coronary-artery stents. N Engl J Med 354:483-495 (2006).
17. Carlsson J, Medikamentenbeschichtete Stents - Verwirrung und Ernüchterung in der invasiven Kardiologie. Dtsch Arztebl 104:A98-A99 (2007).
18. Regar E, Sianos G and Serruys PW, Stent development and local drug delivery. Br Med Bull 59:227-248 (2001). (Pubitemid 34076026)
19. Ranade SV, Miller KM, Richard RE, Chan AK, Allen MJ and Helmus MN, Physical characterization of controlled release of paclitaxel from the TAXUS Express2 drug-eluting stent. J Biomed Mater Res A 71:625-634 (2004).
20. Farb A, Burke AP, Kolodgie FD and Virmani R, Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108:1701-1706 (2003).
21. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al, Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193-202 (2006).
22. Lanzer P, Sternberg K, Schmitz KP, Kolodgie F, Nakazawa G and Virmani R, Drug-eluting coronary stent very late thrombosis revisited. Herz 33:334-342 (2008).
23. Virmani R, Kolodgie FD and Farb A, Drug-eluting stents: are they really safe? Am Heart Hosp J 2:85-88 (2004).
24. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al, Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109:701-705 (2004).
25. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, et al, Comparison of zotarolimus-eluting and sirolimuseluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 48:2440-2447 (2006).
26. Beijk MA and Piek JJ, XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent. Expert Rev Med Devices 4:11-21 (2007).
27. Grube E and Buellesfeld L, BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices 3:731-741 (2006).
28. Mani G, Feldman MD, Patel D and Agrawal CM, Coronary stents: a materials perspective. Biomaterials 28:1689-1710 (2007).
29. Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G, et al, Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 45:1574-1579 (2005).
30. Blindt R, Vogt F, Astafieva I, Fach C, Hristov M, Krott N, et al, A novel drug-eluting stent coated with an integrin-binding cyclic Arg- Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J Am Coll Cardiol 47:1786-1795 (2006).
31. Scheller B,Speck U,Abramjuk C, Bernhardt U,Bohm M andNickenig G, Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 110:810-814 (2004).
32. Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, et al, Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119:2986-2994 (2009).
33. Sheiban I, Anselmino M, Moretti C, Biondi-Zoccai G, Galloni M, Vignolini C, et al, Effect of a novel drug-eluted balloon coated with genistein before stent implantation in porcine coronary arteries. Clin Res Cardiol 97:891-898 (2008).
34. van der GiessenWJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR, Jr., et al, Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94:1690-1697 (1996).
35. Lincoff AM, Furst JG, Ellis SG, Tuch RJ and Topol EJ, Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 29:808-816 (1997).
36. Freier T, Kunze C, Nischan C, Kramer S, Sternberg K, Sass M, et al, In vitro and in vivo degradation studies for development of a biodegradable patch based on poly(3-hydroxybutyrate). Biomaterials 23:2649-2657 (2002).
37. Otsuka Y, Chronos NA, Apkarian RP and Robinson KA, Scanning electronmicroscopic analysisofdefects inpolymer coatingsof three commercially available stents: comparison of BiodivYsio, Taxus and Cypher stents. J Invasive Cardiol 19:71-76 (2007).
38. SchmidtW, Lanzer P, Behrens P, Topoleski LD and Schmitz KP, A comparison of themechanical performance characteristics of seven drug-eluting stent systems. Catheter Cardiovasc Interv 73:350-360 (2009).
39. Sternberg K, Kramer S, Nischan C, Grabow N, Langer T, Hennighausen G et al, In vitro study of drug-eluting stent coatings based on poly(L-lactide) incorporating cyclosporine A - drug release, polymer degradation and mechanical integrity. J Mater Sci: Mater Med 18:1423-1432 (2007).
40. Neubert A, Sternberg K, Nagel S, Harder C, Schmitz KP, Kroemer HK et al,Development of a vessel-simulating flow-through cellmethod for the in vitro evaluation of release and distribution from drugeluting stents. J Control Release 130:2-8 (2008).
41. Ferns GA and Avades TY, The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol 81:63-88 (2000).
42. Schwartz RS, Edelman ER, Carter A, Chronos NA, Rogers C, Robinson KA, et al, Preclinical evaluation of drug-eluting stents for peripheral applications: recommendations from an expert consensus group. Circulation 110:2498-2505 (2004).
43. Colombo A and Karvouni E, Biodegradable stents: 'fulfilling the mission and stepping away'. Circulation 102:371-373 (2000).
44. Zidar J, et al, Biodegradable stents. in Textbook of Interventional Cardiology, 2nd edn. ed. by Topol E. WB Saunders, Philadelphia, pp 787-802 (1994).
45. Erne P, Schier M and Resink TJ, The road to bioabsorbable stents: reaching clinical reality? Cardiovasc Intervent Radiol 29:11-16 (2005).
46. Zilberman M and Eberhart RC, Drug-eluting bioresorbable stents for various applications. Annu Rev Biomed Eng 8:153-180 (2006). (Pubitemid 44314815)
47. Sharkawi T, Cornhill F, Lafont A, Sabaria P and Vert M, Intravascular bioresorbable polymeric stents: a potential alternative to current drug eluting metal stents. J Pharm Sci 96:2829-2837 (2007).
48. Brown DA, Lee EW, Loh CT and Kee ST, A new wave in treatment of vascular occlusive disease: biodegradable stents-clinical experience and scientific principles. J Vasc Interv Radiol 20:315-324 (2009).
49. Stack RS, Califf RM, Phillips HR, Pryor DB, Quigley PJ, Bauman RP, et al, Interventional cardiac catheterization at Duke Medical Center. Am J Cardiol 62:3F-24F (1988).
50. Uurto I, Juuti H, Parkkinen J, Kellomaki M, Keski-Nisula L, Nevalainen T, et al, Biodegradable self-expanding poly-L/D-lactic acid vascular stent: a pilot study in canine and porcine iliac arteries. J Endovasc Ther 11:712-718 (2004). (Pubitemid 40110749)
51. Venkatraman SS, Tan LP, Joso JF, Boey YC and Wang X, Biodegradable stents with elasticmemory. Biomaterials 27:1573-1578 (2006).
52. Wong YS, Xiong Y, Venkatraman SS and Boey FY, Shape memory in un-cross-linked biodegradable polymers. J Biomater Sci Polym Ed 19:175-191 (2008).
53. Venkatraman S, Poh TL, Vinalia T, Mak KH and Boey F, Collapse pressures of biodegradable stents. Biomaterials 24:2105-2111 (2003).
54. Zilberman M, Nelson KD and Eberhart RC, Mechanical properties and in vitro degradation of bioresorbable fibers and expandable fiberbased stents. J Biomed Mater Res B Appl Biomater 74:792-799 (2005). (Pubitemid 41076951)
55. Welch TR, Eberhart RC and Chuong CJ, The influence of thermal treatment on the mechanical characteristics of a PLLA coiled stent. J Biomed Mater Res B Appl Biomater 90:302-311 (2009).
56. Tsuji T, Tamai H, Igaki K, Kyo E, Kosuga K, Hata T, et al, Biodegradable stents as a platform to drug loading. Int J Cardiovasc Intervent 5:13-16 (2003). (Pubitemid 36227310)
57. Alexis F, Venkatraman SS, Rath SK and Boey F, In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stentmatrices. J Control Release 98:67-74 (2004). (Pubitemid 38881608)
58. Vogt F, Stein A, Rettemeier G, Krott N, Hoffmann R, vom Dahl J, et al, Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 25:1330-1340 (2004). (Pubitemid 38998510)
59. Uurto I, Mikkonen J, Parkkinen J, Keski-Nisula L, Nevalainen T, Kellomaki M, et al, Drug-eluting biodegradable poly-D/L-lactic acid vascular stents: an experimental pilot study. J Endovasc Ther 12:371-379 (2005). (Pubitemid 40828046)
60. Grabow N, Schlun M, Sternberg K, Hakansson N, Kramer S and Schmitz KP, Mechanical properties of laser cut poly(L-lactide) micro-specimens: implications for stent design, manufacture, and sterilization. ASME J Biomech Eng 127:25-31 (2005). (Pubitemid 40463478)
61. Grabow N, Bunger C, Sternberg K,Mews S, Schmohl K and Schmitz KP, Mechanical properties of a biodegradable balloon-expandable stent from poly(L-lactide) for peripheral vascular applications. ASME JMedDevices 1:84-88 (2007). (Pubitemid 351780880)
62. SchmidtW, Andresen R, Behrens P and Schmitz KP, [Characteristic mechanical properties of balloon-expandable peripheral stent systems]. Rofo 174:1430-1437 (2002).
63. Bünger CM, Grabow N, Sternberg K, Ketner L, Kröger C, Lorenzen B, et al, Iliac anastomotic stenting with a biodegradable poly-L-lactide stent: a preliminary study after 1 and 6 weeks. J Endovasc Ther 13:539-548 (2006). (Pubitemid 44423048)
64. Bünger CM, Grabow N, Kröger C, Lorenzen B, Hauenstein K, Goosmann M, et al, Iliac anastomotic stenting with a sirolimuseluting biodegradable poly-L-lactide stent: a preliminary study after 6 weeks. J Endovasc Ther 13:630-639 (2006). (Pubitemid 44423048)
65. Grabow N, Bünger CM, Schultze C, Schmohl K, Martin DP, Williams SF, et al, A biodegradable slotted tube stent based on poly(L-lactide) and poly(4-hydroxybutyrate) for rapid balloon-expansion. Ann Biomed Eng 35:2031-2038 (2007). (Pubitemid 350165290)
66. Bünger CM, Grabow N, Sternberg K, Goosmann M, Schmitz KP, Kreutzer HJ, et al, A biodegradable stent based on poly(L-lactide) and poly(4-hydroxybutyrate) for peripheral vascular application: preliminary experience in the pig. J Endovasc Ther 14:725-733 (2007). (Pubitemid 47598200)
67. Martin DP and Williams DF, Medical applications of poly-4- hydroxybutyrate: a strong flexible absorbable material. Biochem Eng J 16:97-105 (2003).
68. Hori Y, Yamaguchi A and Hagiwara T, Chemical synthesis of high molecular weight poly(3-hydroxybutyrate-co-4-hydroxybutyrate). Polymer 36:4703-4705 (1995).
69. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, et al, Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102:399-404 (2000). (Pubitemid 30490677)
70. Tsuji T, Tamai H, Igaki K, Kyo E, Kosuga K, Okada M, et al, The influence of biodegradation of the biodegradable stentonvessel inlong-term period: serial intravascular ultrasound analysis of the Igaki-Tamai biodegradable stent. Circulation 106:356-356 (2002).
71. Biamino G, Schmidt A and Scheinert D, Treatment of SFA lesions with PLLA biodegradable stents: results of the PERSEUS study. J Endovasc Ther 12(Suppl-I-5):(2005).
72. Ormiston JA, Webster MW and Armstrong G, First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv 69:128-131 (2006). (Pubitemid 46052603)
73. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia- Garcia HM, et al, A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373:897-910 (2009).
74. Kohn J and Zeltinger J,Degradable, drug-eluting stents: a new frontier for the treatment of coronary artery disease. Expert RevMed Devices 2:667-671 (2005). (Pubitemid 41699897)
75. PeusterM, Wohlsein P, Brugmann M, Ehlerding M, Seidler K, Fink C, et al, A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal-results 6-18 months after implantation into New Zealand white rabbits. Heart 86:563-569 (2001). (Pubitemid 32999872)
76. Heublein B,Rohde R,Kaese V,Niemeyer M,Hartung W andHaverich A, Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart 89:651-656 (2003).
77. Di Mario C, Griffiths H, Goktekin O, Peeters N, Verbist J, Bosiers M, et al, Drug-eluting bioabsorbable magnesium stent. J Interv Cardiol 17:391-395 (2004).
78. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, et al, Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369:1869-1875 (2007).
79. Waksman R, Erbel R, Di Mario C,Bartunek J,de Bruyne B, Eberli FR, et al, Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC Cardiovasc Interv 2:312-320 (2009).
80. Harder C, Bioabsorbable magnesium stent: an up-date on experimental data and clinics. Presentation at the 14th Local Drug Delivery Meeting and Cardiovascular Course on Revascularization & Molecular Strategies (LDDR), Geneva, Switzerland, February 3 (2007).